Study title: A multicenter European randomized parallel-group phase III study to evaluate safety and efficacy of rHuG-CSF (lenograstim) in the first 12 weeks of the treatment of de novo severe aplastic anemia - 1998 (Blood, 92 (10) suppl 1 : abs 1551, p 376 a)
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Hemic and Lymphatic Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: LENOGRASTIM | |||||
| ATC code: L03AA10 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: GCS-302 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |